{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:18:51Z","timestamp":1791980331208,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009524","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T00:00:00Z","timestamp":1429574400000}}],"reference-count":42,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009524.pub2","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T21:38:56Z","timestamp":1429652336000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Latrepirdine for Alzheimer's disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"Sarah","family":"Chau","sequence":"first","affiliation":[{"name":"University of Toronto; Sunnybrook Health Sciences Centre; 2075 Bayview Avenue Room FG-05 Toronto ON Canada M4N 3M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[{"name":"University of Toronto; Sunnybrook Health Sciences Centre; 2075 Bayview Avenue Room FG-05 Toronto ON Canada M4N 3M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myuri T","family":"Ruthirakuhan","sequence":"additional","affiliation":[{"name":"University of Toronto; Neuropsychopharmacology; 2075 Bayview Avenue Toronto ON Canada M4N 3M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan Jenny","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Toronto; Pharmacology and Toxicology; Medical Sciences Building Rm 4207, 1 King's College Circle Toronto ON Canada M5S 1A8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L","family":"Lanct\u00f4t","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute; Brain Sciences Research Program; 2075 Bayview Ave. Room FG-08 Toronto ON Canada M4N 3M5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,21]]},"reference":[{"key":"10.1002\/14651858.CD009524.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/JAD-130872","article-title":"Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: a meta-analysis","volume":"38","author":"Cano-Cuenca","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0002|cit2","unstructured":"Medivation Inc Pfizer CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1002\/14651858.CD009524.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/JAD-130872","article-title":"Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: a meta-analysis","volume":"38","author":"Cano-Cuenca","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0004|cit4","unstructured":"Medivation Inc Pfizer A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1002\/14651858.CD009524.pub2-BIB0005|cit5","unstructured":"Medivation Inc Pfizer A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease (CONTACT) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1002\/14651858.CD009524.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0007|cit7","unstructured":"Pfizer Medivation Inc A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1002\/14651858.CD009524.pub2-BIB0008|cit8","unstructured":"Medivation Inc Pfizer A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1002\/14651858.CD009524.pub2-BIB0009|cit9","first-page":"P251","article-title":"A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil","volume":"5 Suppl","author":"Tariot","year":"2009","journal-title":"Alzheimer's & Dementia"},{"issue":"2","key":"10.1002\/14651858.CD009524.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jalz.2010.01.009","article-title":"2010 Alzheimer's disease facts and figures","volume":"6","author":"Alzheimer\u2019s Association","year":"2010","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0011|cit11","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/bss0670073","article-title":"Sites of phosphorylation in tau and factors affecting their regulation","volume":"67","author":"Anderton","year":"2001","journal-title":"Biochemical Society Symposia"},{"issue":"11","key":"10.1002\/14651858.CD009524.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0895-4356(03)00175-6","article-title":"Use of the EQ-5D among patients suffering from dementia","volume":"56","author":"Ankri","year":"2003","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1749-6632.2001.tb03654.x","article-title":"Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer","volume":"939","author":"Bachurin","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1749-6632.2003.tb07541.x","article-title":"Mitochondria as a target for neurotoxins and neuroprotective agents","volume":"993","author":"Bachurin","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD009524.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00023210-200923040-00003","article-title":"Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease","volume":"23","author":"Bassil","year":"2009","journal-title":"CNS Drugs"},{"issue":"Art. No.: CD005","key":"10.1002\/14651858.CD009524.pub2-BIB0017|cit17","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer\u2019s disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/JAD-130872","article-title":"Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: a meta-analysis","volume":"38","author":"Cano-Cuenca","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD009524.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00019442-200005000-00008","article-title":"The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease","volume":"8","author":"Cummings","year":"2000","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD009524.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(04)90172-5","article-title":"Effects of rivastigmine on behavioural and psychological symptoms of dementia in Alzheimer's disease","volume":"26","author":"Finkel","year":"2004","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Galasko","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1002\/14651858.CD009524.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/jnnp.2006.109074","article-title":"Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination","volume":"78","author":"Henzel","year":"2007","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt49","article-title":"Dimebon disappointment","volume":"2","author":"Jones","year":"2010","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"10.1002\/14651858.CD009524.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pnpbp.2007.07.018","article-title":"Dimenhydrinate effect on cerebral oxygen status and salivary chromogranin-A during cognitive tasks","volume":"32","author":"Kanamarua","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD009524.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1002\/14651858.CD009524.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neurobiolaging.2006.03.013","article-title":"NSAIDs and Alzheimer's disease: epidemiological, animal, model and clinical studies","volume":"28","author":"McGreer","year":"2007","journal-title":"Neurobiology of Aging"},{"issue":"7","key":"10.1002\/14651858.CD009524.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"Art. No.: CD003","key":"10.1002\/14651858.CD009524.pub2-BIB0034|cit34","article-title":"Memantine for dementia","author":"McShane","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1741-7015-7-7","article-title":"Recent developments in Alzheimer's disease therapeutics","volume":"7","author":"Rafii","year":"2009","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0036|cit36","first-page":"8","article-title":"Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines","volume":"11 Suppl 3","author":"Reisberg","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Schneider","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"2","key":"10.1002\/14651858.CD009524.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009524.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-1326-6-7","article-title":"Preclinical study of dimebon on B-amyloid-mediated neuropathy in Alzheimer's disease","volume":"6","author":"Wang","year":"2011","journal-title":"Molecular Neurodegeneration"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1041610297004298","article-title":"Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial","volume":"9","author":"Weyer","year":"1997","journal-title":"International Psychogeriatrics"},{"issue":"8","key":"10.1002\/14651858.CD009524.pub2-BIB0041|cit41","first-page":"685","article-title":"The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia","volume":"14","author":"Wimo","year":"2010","journal-title":"Journal of Nutrition"},{"key":"10.1002\/14651858.CD009524.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-1326-3-15","article-title":"Evaluation of Dimebon in cellular model of Huntington's disease","volume":"3","author":"Wu","year":"2008","journal-title":"Molecular Neurodegeneration"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009524.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T10:47:04Z","timestamp":1707043624000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009524.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,21]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009524.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,21]]}}}